The need for physiological phenotyping to develop new drugs for airways disease.
Pharmacol Res
; 159: 105029, 2020 09.
Article
em En
| MEDLINE
| ID: mdl-32565310
ABSTRACT
Asthma and COPD make up the majority of obstructive airways diseases (OADs), which affects â¼11 % of the population. The main drugs used to treat OADs have not changed in the past five decades, with advancements mainly comprising variations on existing treatments. The recent biologics are beneficial to only specific subsets of patients. Part of this may lie in our inability to adequately characterise the tremendous heterogeneity in every aspect of OAD. The field is currently moving towards the concept of personalised medicine, based on a focus on treatable traits that are objective, measurable and modifiable. We propose extending this concept via the use of emerging clinical tools for comprehensive physiological phenotyping. We describe, based on published data, the evidence for the use of functional imaging, gas washout techniques and oscillometry, as well as potential future applications, to more comprehensively assess and predict treatment response in OADs. In this way, we hope to demonstrate how physiological phenotyping tools will improve the way in which drugs are prescribed, but most importantly, will facilitate development of new drugs for OADs.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Testes de Função Respiratória
/
Obstrução das Vias Respiratórias
/
Pulmão
/
Pneumopatias Obstrutivas
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article